Current screening protocols fail to catch a notable number of people carrying genetic mutations associated with hereditary breast and ovarian cancer syndrome and Lynch syndrome, which increase the risk of developing certain cancers. This issue is particularly pronounced among underrepresented minorities.
Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a recent study led by researchers at NYU Langone Health and its Perlmutter Cancer Center shows.
